uploads/2018/11/SYK4.png

Analysts Remain Bullish on Stryker Stock

By

Updated

Analysts’ recommendations

In November 2018, of the total 29 analysts covering Stryker (SYK), 19 analysts gave Stryker stock a “buy” or higher rating, and ten analysts gave it a “hold” rating. The mean rating for Stryker stock is 1.97 with a target price of $187.32, implying an upside potential of 11.7% over Stryker’s closing price of $167.72 on November 19, 2018.

Article continues below advertisement

Peer ratings

In comparison, for peers Abbott Laboratories (ABT), Johnson & Johnson (JNJ), and Zimmer Biomet Holdings (ZBH) analysts have a mean rating of 1.8, 2.32, and 2.31, respectively, and a target price of $78.94, $146.78, and $134.88, respectively.

The enterprise value of Stryker is $69.41 billion, and its enterprise-value-to-revenue ratio is 5.23x. The stock is trading at a forward PE multiple of 21.07x. Its price-to-sales ratio is 4.73x, and its price-to-book ratio is 6.36x. In comparison, the price-to-book ratio of its peers Abbott Laboratories (ABT), Johnson & Johnson (JNJ), and Zimmer Biomet Holdings (ZBH) stands at 4.04, 6.13, and 1.89, respectively.

Its current ratio, a metric of how effectively a company can meet its short-term obligations, stands at 1.90x. In comparison, the current ratio of peers Abbott Laboratories (ABT), Johnson & Johnson (JNJ), and Zimmer Biomet Holdings (ZBH) stands at 1.40x, 1.70x, and 1.90x, respectively.

Stryker’s cash per share stands at $5.91. In comparison, the cash per share of peers Abbott Laboratories (ABT), Johnson & Johnson (JNJ), and Zimmer Biomet Holdings (ZBH) stands at $4.30, $7.22, and $2.57, respectively.

Advertisement

More From Market Realist